SCHAUMBURG, Ill., Oct. 18 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the commercial launch of ANEclear™, an easy-to-use, disposable anesthesia recovery device at the American Society of Anesthesia (ASA) meeting in San Diego.
Approximately 23 million surgical procedures are performed annually in the United States involving general anesthesia using inhaled anesthetic gases. ANEclear is the only FDA cleared device that offers clinicians a simple method to rapidly remove unwanted anesthetic gases from their patients' brain, blood and lungs at the end of the surgical procedure. ANEclear's patented design allows patients to partially rebreathe their own exhaled carbon dioxide while trapping the most commonly used volatile gases. ANEclear's accelerated wash-out of these volatile anesthetics provides for significantly shorter patient anesthesia recovery times and surgical wake-ups.
"ANEclear is an important tool for anesthesia providers and recovery room caregivers to accelerate patient emergence in both the outpatient and inpatient setting," said Jeffrey M. Yordon, chief executive officer, founder and chairman of the board, Sagent Pharmaceuticals, Inc. "The launch of this innovative device further demonstrates Sagent's commitment to introducing unique solutions in response to the needs of caregivers and patients."
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products th